Related Experiment Videos
[Mechanism on androgen-independent progression of prostate cancer]
J Shimazaki1, K Akakura, Y Furuya
1Department of Urology, School of Medicine, Chiba University.
Abstract:
Eighty percent of prostate cancer with metastasis respond to androgen ablasion, showing initial androgen-sensitive growth. However, more than half of responders gradually loses dependency up to 5 years. Animal experiments reveal that loss of androgen sensitivity is attributable to complex reasons; adaptation, paracrine control by other androgen-independent tissues, genetic changes and mutation of androgen receptor. Most important event is explained from alteration of expression on oncogenes and suppressor genes. Counterplan of the progression was discussed.
Insights
Most prostate cancers initially respond to androgen ablation therapy. However, resistance develops within five years due to complex genetic and cellular changes, necessitating new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Metastatic prostate cancer often initially responds to androgen ablation therapy.
- Resistance to androgen deprivation therapy (ADT) develops in over half of patients within five years.
- Understanding the mechanisms of ADT resistance is crucial for improving patient outcomes.
Purpose:
- To investigate the complex reasons behind the loss of androgen sensitivity in metastatic prostate cancer.
- To identify key molecular events, including genetic alterations and changes in oncogene/suppressor gene expression, contributing to treatment resistance.
- To discuss potential counterplans for managing the progression of resistant prostate cancer.
Summary:
- Eighty percent of metastatic prostate cancers initially respond to androgen ablation, demonstrating androgen-sensitive growth.
- Loss of androgen sensitivity occurs gradually within five years, driven by adaptation, paracrine signaling, and genetic mutations, including androgen receptor changes.
- Alterations in oncogene and suppressor gene expression are identified as critical events in the development of resistance.
Impact:
- Provides insights into the molecular mechanisms underlying acquired resistance to androgen deprivation therapy in prostate cancer.
- Highlights the importance of genetic alterations and gene expression changes in treatment failure.
- Informs the development of novel therapeutic strategies to overcome or prevent androgen-independent progression.